Cell Line Development
Holly Prentice has over 20 years of experience developing cell lines, manufacturing processes and analytical methods for biologics. Her expertise also includes the identification and management of CMOs and CROs in these areas. Dr. Prentice has been involved in CMC development for a number of biotherapeutics and specializes in the selection and development of recombinant protein expression platforms and cell culture media. Before taking up consulting, she was Associate Director of Biologics Process Development at Momenta Pharmaceuticals where she oversaw the use of proprietary expression technologies. Prior to her time at Momenta, she held senior management positions at Millipore and helped develop a mammalian expression vector and cell line for biotherapeutic production. At Biogen Idec, Dr. Prentice led several teams that developed clinical and commercial processes, which included CMC related activities for IND filing.